Fibrogen, Inc. v. Hangzhou Andao Pharmaceutical LTD.
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA SAN JOSE DIVISION 7 FIBROGEN, INC., Case No. 5:22-cv-07148-EJD
Plaintiff, ORDER GRANTING MOTION TO
STAY DISCOVERY PENDING
v. DISPOSITIVE MOTION
HANGZHOU ANDAO PHARMACEUTICAL LTD., et al., Re: ECF Nos. 34, 35 12 Defendants.
13 Defendants Hangzhou Andao Pharmaceutical Ltd., Kind Pharmaceuticals LLC, Dr. 14 Dongliu, and Dr. Shaojiang Deng (“Defendants”) move for a Rule 26(c) protective order to stay 15 discovery (“Motion”) until their motion to dismiss has been resolved. ECF No. 34. 16 The Court finds that this matter is suitable for disposition without oral argument and 17 thereby VACATES the August 17, 2023 hearing on the Motion.
I. PROCEDURAL BACKGROUND
19 On November 14, 2022, Plaintiff FibroGen, Inc. filed this action, asserting patent 20 inventorship and breach of contract claims against two of its former scientists and the companies 21 they started. ECF No. 1. 22 On February 7, 2023, Defendants moved to dismiss the Complaint. …